Danish drugmaker Novo Nordisk has partnered Emcure Pharmaceuticals to commercialise Poviztra, a 2.4 milligram (mg) ...

Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure ...

Novo Nordisk partners with Emcure to promote Wegovy, following Eli Lilly's recent collaboration with Cipla for tirzepatide in ...

The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them more affordable and accessible ...

Middle-class Indians trying to lose weight are embracing drugs such as Mounjaro, which is also used to treat diabetes in a ...

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook ...

President Donald Trump announced major GLP-1 drug price cuts with Eli Lilly and Novo Nordisk, reducing costs for Ozempic and Wegovy.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk ...

TrumpRx will offer Novo Nordisk's Ozempic and Wegovy through TrumpRx for $350 and Eli Lilly and Company's Zepbound and ...

Our Bureau, Mumbai Monday, November 10, 2025, 12:45 Hrs [IST] ...